生命科学资讯

Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M

Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data

'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out

How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle

A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine

Bristol Myers expands Breyanzi approval to marginal zone lymphoma

Money raised by biopharma

Biopharma money raised: Jan. 1-Dec. 4, 2025

BioWorld and Nasdaq stock indices

ACIP drops universal hepatitis B birth dose recommendation

NICE adds further details on how the UK will pay more for drugs

Biopharma money raised by quarter in 2025 (US$M)

Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara

Rapport shares updated results from Phase 2 study of seizure drug

Autoantibody-triggered podocyte membrane budding drives autoimmune kidney disease

Renal PIEZO2 is an essential regulator of renin

A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis

Chutes & Ladders—Yet another CDER leadership shake-up

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA

Cancer blood test developer Freenome to go public in $330M SPAC deal